Abstract

BackgroundType 1 diabetes is an autoimmune disease caused by T cell-mediated destruction of the insulin-producing β-cells in the pancreas. Therefore, approaches that effectively halt the pathogenic T cell response are predicted to have preventive or therapeutic benefit for type 1 diabetes patients. We previously demonstrated that long-term blocking of IL-7 signaling, which is critical for the survival and function of T cells, prevented and reversed type 1 diabetes in non-obese diabetic mice. However, such persistent inhibition of T cell responses raises concerns about causing immunodeficiency. Here, we asked whether a reduced duration of the treatment with anti-IL-7Rα antibodies retained efficacy in preventing diabetes. Moreover, we sought to identify immunoregulatory mechanisms induced by anti-IL-7Rα administration.ResultsAnti-IL-7Rα antibodies were administered to prediabetic NOD mice for 3 weeks and blood samples were taken at the end of treatment and 2 weeks later to analyze changes in T cell phenotypes in response to IL-7Rα blockade. We found that the co-inhibitory receptors LAG-3, Tim-3 and PD-1 were increased on peripheral blood CD4+ and CD8+ T cells from anti-IL-7Rα-treated mice. Expression of these receptors contributed to reduced T cell cytokine production in response to TCR stimulation. In addition, the frequency of Tregs within the circulating CD4+ T cells was increased at the end of anti-IL-7Rα antibody treatment and these Tregs showed a more activated phenotype. In vitro restimulation assays revealed that effector T cells from anti-IL-7Rα-treated mice were more sensitive to co-inhibitory receptor induction after TCR stimulation. Importantly, these changes were accompanied by delayed type 1 diabetes disease kinetics.ConclusionsTogether, our data show that short-term blockade of IL-7Rα induces detectable changes in co-inhibitory receptor expression and Treg frequencies in peripheral blood of NOD mice. These changes appear to have long-lasting effects by delaying or preventing type 1 diabetes incidence. Hence, our study provides further support for using anti-IL-7Rα antibodies to modulate autoreactive T cell responses.

Highlights

  • Type 1 diabetes is an autoimmune disease caused by T cell-mediated destruction of the insulinproducing β-cells in the pancreas

  • We found that in addition to PD-1, LAG-3 and Tim-3 were induced on T cells in response to IL-7Rα blockade

  • In the group that received rat IgG, mice started to become hyperglycemic at 12 weeks of age, whereas the mice treated with anti-IL-7Rα monoclonal antibodies (mAbs) showed a significant delay in diabetes onset (Fig. 1b)

Read more

Summary

Introduction

Type 1 diabetes is an autoimmune disease caused by T cell-mediated destruction of the insulinproducing β-cells in the pancreas. We previously demonstrated that long-term blocking of IL-7 signaling, which is critical for the survival and function of T cells, prevented and reversed type 1 diabetes in non-obese diabetic mice. Such persistent inhibition of T cell responses raises concerns about causing immunodeficiency. We and others previously demonstrated that blocking IL-7 receptor alpha (IL-7Rα) prevented and reversed diabetes in non-obese diabetic (NOD) mice and has potential to be translated as an immunotherapy for human type 1 diabetes [4, 5]. Initial analyses of CD4+ T cells in anti-IL-7Rα-treated mice revealed increased

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call